Thymalin and Vesilute Interaction: Compatible | Peptide Database

Join others researching Anastrozole — share findings, ask questions, and learn from real experiences Anastrozole is a potent, selective, nonsteroidal aromatase inhibitor that blocks the enzyme aromatase (CYP19A1), preventing the conversion of androgens (testosterone and androstenedione) into estrogens (estradiol and estrone). It is FDA-approved under the brand name Arimidex for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In the bodybuilding and hormone optimization community, anastrozole is widely used as an ancillary compound during testosterone or anabolic steroid cycles to manage estrogen-related side effects such as gynecomastia, water retention, and elevated blood pressure. Unlike SERMs, which block estrogen at the receptor, anastrozole reduces circulating estrogen levels directly by inhibiting its synthesis. This distinction is clinically important: while effective at preventing estrogenic side effects, anastrozole carries the risk of suppressing estrogen too aggressively, which can impair joint health, bone density, cardiovascular markers, and mood. A common starting-point rule of thumb: weekly testosterone dose (mg) divided by 500 equals mg of anastrozole per week. For example, 500 mg of testosterone per week would correspond to roughly 1 mg of anastrozole per week, split across injection days. This is only a rough guideline -- individual aromatization rates vary widely, and dosing should always be refined based on bloodwork. Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain. By blocking this conversion, anastrozole reduces circulating estradiol concentrations by approximately 70-80% at the standard 1mg daily dose. In men using exogenous testosterone, aromatase activity is upregulated due to elevated substrate availability, leading to supraphysiological estradiol. Anastrozole counteracts this by limiting estrogen synthesis at the enzymatic level. The inhibition is reversible, meaning estrogen production resumes once the drug is cleared, unlike exemestane which irreversibly inactivates aromatase. Because estrogen plays essential physiological roles in men -- including bone metabolism, lipid homeostasis, neurocognition, and joint lubrication -- the goal of anastrozole use is modulation rather than elimination.

Irreversibly inactivates aromatase to reduce estradiol levels during testosterone or aromatizable anabolic steroid cycles. The absence of estrogen rebound makes exemestane particularly useful when discontinuing AI support, such as transitioning into PCT. Manages estrogen-mediated fluid retention and subcutaneous bloating common with testosterone and other aromatizable compounds. The mild androgenic activity of exemestane may complement the drier appearance. Titrated to keep estradiol within a healthy range during hormone replacement or enhancement protocols. Because inhibition is irreversible, overshooting the dose requires waiting for new aromatase synthesis rather than simply skipping doses. Bloodwork is essential. FDA-approved for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy, and as adjuvant therapy after 2-3 years of tamoxifen. The IES trial demonstrated improved disease-free survival when switching to exemestane after initial tamoxifen treatment. Used off-label alongside TRT to manage estradiol elevations. The irreversible mechanism and mild androgenic properties make it an alternative to anastrozole for men who experience excessive joint pain or mood disturbance on nonsteroidal AIs. Exemestane's irreversible mechanism prevents the estrogen rebound that can occur when stopping a reversible AI like anastrozole at the end of a cycle. This makes it well-suited for managing estrogen during the transition into post-cycle therapy with SERMs.